| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
179,400,000 |
| Market
Cap: |
313.95(M) |
| Last
Volume: |
1,560,200 |
Avg
Vol: |
2,306,261 |
| 52
Week Range: |
$0.449 - $1.83 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for cancer and autoimmune disease. Co.'s proprietary programs include: Immuno-oncology, which involves in developing medicines that target biological pathways which stimulate and sustain the body's immune response in order to fight cancer; and Pain, NKTR-181, a mu-opioid analgesic drug candidate patients with chronic low back pain. Co.'s NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
92,653 |
92,653 |
204,995 |
510,803 |
| Total Sell Value |
$124,554 |
$124,554 |
$194,453 |
$1,231,647 |
| Total People Sold |
4 |
4 |
7 |
10 |
| Total Sell Transactions |
4 |
4 |
13 |
34 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2018-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,400 |
76,148 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2018-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
60,500 |
284,856 |
|
- |
|
| Labrucherie Gil M |
SVP & Chief Financial Officer |
• – – |
2018-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
26,000 |
121,266 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2018-08-14 |
4 |
D |
$60.08 |
$2,403,200 |
D/D |
(40,000) |
224,356 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2018-08-14 |
4 |
A |
$10.69 |
$427,600 |
D/D |
40,000 |
264,356 |
|
- |
|
| Winger Dennis L |
Director |
– • – |
2018-08-14 |
4 |
S |
$60.15 |
$1,030,069 |
D/D |
(17,125) |
42,750 |
|
- |
|
| Winger Dennis L |
Director |
– • – |
2018-08-13 |
4 |
S |
$61.04 |
$1,045,310 |
D/D |
(17,125) |
59,875 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2018-06-27 |
4 |
AS |
$47.39 |
$2,053,551 |
D/D |
(43,333) |
224,356 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2018-06-27 |
4 |
OE |
$10.69 |
$463,230 |
D/D |
43,333 |
267,689 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2018-06-26 |
4 |
AS |
$49.36 |
$2,138,917 |
D/D |
(43,333) |
224,356 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2018-06-26 |
4 |
OE |
$10.69 |
$463,230 |
D/D |
43,333 |
267,689 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2018-06-25 |
4 |
AS |
$51.82 |
$2,245,568 |
D/D |
(43,334) |
224,356 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2018-06-25 |
4 |
OE |
$10.69 |
$463,240 |
D/D |
43,334 |
267,690 |
|
- |
|
| Whitfield Roy A |
Director |
– • – |
2018-06-06 |
4 |
B |
$59.07 |
$201,860 |
D/D |
3,400 |
177,000 |
2.39 |
- |
|
| Greer R Scott |
Director |
– • – |
2018-06-06 |
4 |
AS |
$60.00 |
$516,000 |
D/D |
(8,600) |
130,333 |
|
- |
|
| Greer R Scott |
Director |
– • – |
2018-06-06 |
4 |
OE |
$5.14 |
$44,204 |
D/D |
8,600 |
138,933 |
|
- |
|
| Chess Robert |
Director |
– • – |
2018-06-05 |
4 |
AS |
$55.16 |
$551,600 |
D/D |
(10,000) |
274,223 |
|
- |
|
| Chess Robert |
Director |
– • – |
2018-06-05 |
4 |
OE |
$14.26 |
$142,600 |
D/D |
10,000 |
284,223 |
|
- |
|
| Whitfield Roy A |
Director |
– • – |
2018-06-05 |
4 |
B |
$55.22 |
$88,352 |
D/D |
1,600 |
173,600 |
2.39 |
- |
|
| Greer R Scott |
Director |
– • – |
2018-06-04 |
4 |
AS |
$61.99 |
$86,786 |
D/D |
(1,400) |
130,333 |
|
- |
|
| Greer R Scott |
Director |
– • – |
2018-06-04 |
4 |
OE |
$5.14 |
$7,196 |
D/D |
1,400 |
131,733 |
|
- |
|
| Doberstein Stephen K |
SVP & Chief Scientific Officer |
• – – |
2018-05-16 |
4 |
S |
$83.39 |
$286,445 |
D/D |
(3,435) |
63,959 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2018-05-16 |
4 |
S |
$83.39 |
$298,203 |
D/D |
(3,576) |
65,281 |
|
- |
|
| Labrucherie Gil M |
SVP & Chief Financial Officer |
• – – |
2018-05-16 |
4 |
S |
$83.39 |
$412,030 |
D/D |
(4,941) |
94,798 |
|
- |
|
| Hora Maninder |
SVP Pharma Dev & Mfg Ops |
• – – |
2018-05-16 |
4 |
S |
$83.39 |
$338,563 |
D/D |
(4,060) |
76,201 |
|
- |
|
913 Records found
|
|
Page 14 of 37 |
|
|
